Summary & Overview
HCPCS J2357: Injection, omalizumab, 5 mg
HCPCS Level II code J2357 denotes a 5 mg unit of omalizumab, a monoclonal antibody used as an injectable biologic. Nationally, this billing code matters because it standardizes reporting for dosing and reimbursement of omalizumab across outpatient infusion and ambulatory injection settings, affecting cost tracking, utilization monitoring, and payer coverage determinations.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, reimbursement benchmarks where available, and the clinical context for use of omalizumab as an injectable biologic. The publication covers typical service lines and sites of care, common billing modifiers associated with drug and administration claims, and how J2357 maps to dosing documentation.
This analysis provides practical reference material for coding teams, revenue cycle professionals, and policy analysts: an explanation of what the code represents, payer inclusion for national benchmarking, and the clinical setting in which the code is commonly used. Data not provided in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J2357 describes injection, omalizumab, 5 mg. This code represents a billed unit of the monoclonal antibody omalizumab, typically administered as a parenteral therapy.
Service Type: Drug administration / injectable biologic
Typical Site of Service: Outpatient infusion or injection settings, including physician offices, outpatient clinics, and other ambulatory care locations where injectable biologic therapies are given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent with moderate-to-severe persistent allergic asthma or chronic idiopathic urticaria who has failed or is inadequately controlled on standard therapy. The patient presents to an outpatient infusion/ injection clinic, allergy/immunology office, or hospital outpatient clinic for administration of J2357 (omalizumab 5 mg). Prior to the visit, the ordering provider documents indication, baseline serum IgE and weight (for asthma dosing considerations), and confirms prior authorization or payer coverage. On arrival, nursing performs pre-injection assessment including vital signs, review of allergy/anaphylaxis history, and confirmation of site-of-care consent. Omalizumab is supplied as a clinic-administered injectable; each vial/unit is billed in 5 mg increments using J2357. The clinician or RN prepares and administers the subcutaneous injection, observes the patient for 30 minutes for potential hypersensitivity or anaphylaxis, and documents lot number, dose, route, site, and any immediate reactions. Subsequent doses follow a scheduled maintenance plan (typically every 2–4 weeks for asthma; frequency varies for urticaria), with ongoing documentation of therapeutic response and adverse events. Billing uses J2357 multiplied by the number of 5 mg units dispensed; appropriate place-of-service and professional vs facility components are captured via modifiers and claim form fields.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|